98 related articles for article (PubMed ID: 19959083)
41. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
42. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
43. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
44. [Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon].
Egyed M; Mihályfalvi Z; Kollár B; Rumi G; Keller E; Vass J; Fekete S
Orv Hetil; 2001 Nov; 142(44):2421-5. PubMed ID: 11766235
[TBL] [Abstract][Full Text] [Related]
45. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
46. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
47. Autotransplantation for chronic myeloid leukemia: is it useful?
Olavarria E
Haematologica; 2002 Jan; 87(1):3-6. PubMed ID: 11801458
[No Abstract] [Full Text] [Related]
48. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
Michor F
Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
[TBL] [Abstract][Full Text] [Related]
49. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
51. PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells.
Glodkowska-Mrowka E; Manda-Handzlik A; Stelmaszczyk-Emmel A; Seferynska I; Stoklosa T; Przybylski J; Mrowka P
Blood Cancer J; 2016 Jan; 6(1):e377. PubMed ID: 26745851
[No Abstract] [Full Text] [Related]
52. PPARγ: Welcoming the New Kid on the CML Stem Cell Block.
Apsel Winger B; Shah NP
Cancer Cell; 2015 Oct; 28(4):409-411. PubMed ID: 26461088
[TBL] [Abstract][Full Text] [Related]
53. Cancer: Repositioned to kill stem cells.
Holyoake T; Vetrie D
Nature; 2015 Sep; 525(7569):328-9. PubMed ID: 26331538
[No Abstract] [Full Text] [Related]
54. Interferon and chronic myelogenous leukaemia.
Lauta VM
Med Oncol; 1995 Mar; 12(1):41-6. PubMed ID: 8542246
[TBL] [Abstract][Full Text] [Related]
55. Haematological cancer: Repositioned to attack CML cells.
Killock D
Nat Rev Clin Oncol; 2015 Nov; 12(11):624. PubMed ID: 26391777
[No Abstract] [Full Text] [Related]
56. AraC-based pharmacotherapy of chronic myeloid leukaemia.
Reiter A; Hochhaus A; Berger U; Kuhn C; Hehlmann R
Expert Opin Pharmacother; 2001 Jul; 2(7):1129-35. PubMed ID: 11583064
[TBL] [Abstract][Full Text] [Related]
57. Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology.
van Kooten Niekerk PB; Roug AS; Petersen CC; Ommen HB; Kjeldsen E; Bendix K; Nyvold CG; Nederby L; Hokland P
Br J Haematol; 2013 Jul; 162(1):141-4. PubMed ID: 23593974
[No Abstract] [Full Text] [Related]
58. Interferon-induced vasospasm in chronic myeloid leukaemia.
Zeidman A; Dicker D; Mittelman M
Acta Haematol; 1998; 100(2):94-6. PubMed ID: 9792941
[TBL] [Abstract][Full Text] [Related]
59. Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment.
Preisler HD; Gopal V
Leuk Res; 1994 Mar; 18(3):149-60; discussion 161. PubMed ID: 7511189
[TBL] [Abstract][Full Text] [Related]
60. Metachronous chronic myeloid leukaemia occurring with background multiple myeloma.
Yeung J; Khoo L
Pathology; 2020 Apr; 52(3):377-379. PubMed ID: 32107078
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
